Jiri Sonek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jiri Sonek has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Kypros Herodotos Nicolaides
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital London UK
4 shared publications - Adam Kinney Hiett
Department of Obstetrics and Gynecology, Wright State University, Boonshoft School of Medicine, Dayton, OH
3 shared publications Cathy Downing
Department of Maternal Fetal Medicine, Miami Valley Hospital, Dayton, USA
2 shared publicationsDavid McKenna
Wright State University, Dayton, OH
2 shared publicationsA. Bombrys
SouthView Hospital, United States
1 shared publicationA. K. Hiett
Fetal Medicine Foundation USA, Dayton, OH, USA
1 shared publication
Latest Publications
- 25 January 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (1) , 175-181
A pragmatic evaluation of the implementation and acceptance of a universal second trimester cervical length screening program in an un-selected population
Purpose To evaluate patients' acceptance of a universal transvaginal ultrasound cervical length (CL) screening program and the feasibility of initiating treatment with progesterone in a clinical setting in women found to have a short cervix. Methods An observational, pragmatic cohort study was conducted at one tertiary care facility from 2012–2015, involving eligible women with singleton pregnancies who accepted and underwent second-trimester CL screening. The primary outcomes were the percentage of women who were eligible and accepting of screening, compliance with progesterone treatment, and the screening value of TVCL in predicting SPTB. Secondary outcomes were the number of women who received progesterone treatment and the rates of SPTB. Results Overall cervical length screening acceptance rate was found to be 82.5%. Of the 797 women that underwent screening, 21 women (2.6%) had a TVCL < 25 mm, of whom nine had a TVCL < 20.0 mm. Nineteen of the 21 women with a TVCL < 25 mm were treated with progesterone, with a 94.7% compliance rate. Delivery outcomes were obtained for 767 women. Of those with a TVCL < 25 mm, there was a 35% rate of SPTB as opposed to a 6.3% SPTB rate in those with TVCL > 25 mm. The negative predictive value for SPTB with a TVCL 25 mm or greater was 94.0%. Conclusion Universal cervical length screening was successfully implemented in 82.5% of the patient population with a high compliance rate with progesterone treatment. Furthermore, there was a higher rate of SPTB in those with a shorter cervix. Based on our outcomes obtained in an observational and pragmatic manner, we showed that incorporating second trimester transvaginal cervical length screening into routine clinical practice is readily accepted and, with the addition of vaginal progesterone treatment, may reduce the rate of prematurity.
- 25 January 2023
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (1) , 175-181
A pragmatic evaluation of the implementation and acceptance of a universal second trimester cervical length screening program in an un-selected population
Purpose To evaluate patients' acceptance of a universal transvaginal ultrasound cervical length (CL) screening program and the feasibility of initiating treatment with progesterone in a clinical setting in women found to have a short cervix. Methods An observational, pragmatic cohort study was conducted at one tertiary care facility from 2012–2015, involving eligible women with singleton pregnancies who accepted and underwent second-trimester CL screening. The primary outcomes were the percentage of women who were eligible and accepting of screening, compliance with progesterone treatment, and the screening value of TVCL in predicting SPTB. Secondary outcomes were the number of women who received progesterone treatment and the rates of SPTB. Results Overall cervical length screening acceptance rate was found to be 82.5%. Of the 797 women that underwent screening, 21 women (2.6%) had a TVCL < 25 mm, of whom nine had a TVCL < 20.0 mm. Nineteen of the 21 women with a TVCL < 25 mm were treated with progesterone, with a 94.7% compliance rate. Delivery outcomes were obtained for 767 women. Of those with a TVCL < 25 mm, there was a 35% rate of SPTB as opposed to a 6.3% SPTB rate in those with TVCL > 25 mm. The negative predictive value for SPTB with a TVCL 25 mm or greater was 94.0%. Conclusion Universal cervical length screening was successfully implemented in 82.5% of the patient population with a high compliance rate with progesterone treatment. Furthermore, there was a higher rate of SPTB in those with a shorter cervix. Based on our outcomes obtained in an observational and pragmatic manner, we showed that incorporating second trimester transvaginal cervical length screening into routine clinical practice is readily accepted and, with the addition of vaginal progesterone treatment, may reduce the rate of prematurity.
- 28 September 2021
- Published by Wiley in Prenatal Diagnosis
- Vol. 41 (13) , 1701-1708
Identification of fetal aneuploidy with dual‐probe fluorescence in situ hybridization analysis in circulating trophoblasts after enrichment using a high‐sensitivity microfluidic platform
Objective To evaluate a microfluidics-based positive selection technology for isolating circulating trophoblasts (CTs) from peripheral blood of women whose pregnancies are affected by aneuploidy and to evaluate fetal karyotype using fluorescence in situ hybridization (FISH). Method Ten 18-ml samples of peripheral blood were collected consecutively from pregnant women whose fetus was affected by aneuploidy. A preservation buffer was added, and the specimens were shipped overnight to the testing laboratory at ambient temperature. The specimen was infused into the fully automated microfluidics-based LiquidScan® instrument without pre-processing. This instrument contains microfluidic chips, which are coated with antibodies (anti-huEpCAM and a proprietary antibody mixture) specific to CT surface epitopes. FISH analysis was performed on the enriched cells. Results Fetal aneuploidy evaluated included trisomy 21 (n = 3), trisomy 18 (n = 1), trisomy 13 (n = 1), monosomy X (n = 3), and triploidy (n = 1). CTs for analysis by FISH were identified in all samples. The average number of mononucleate cells per 1 ml of whole blood was 2.11 (range 0.38–4.63) overall and was 2.67 (range 1.13–4.63) using the proprietary combination of antibodies. FISH results were concordant with the aneuploidy based on other testing in all cases. Multinucleate cells were searched for and identified in the last seven samples (average number: 0.84/1 ml). Conclusions Our study demonstrates that the LiquidScan®, a high-sensitivity microfluidic platform, can enrich circulating trophoblasts (mononucleate and multinucleate). FISH can then be used to detect fetal aneuploidy.
- 28 September 2021
- Published by Wiley in Prenatal Diagnosis
- Vol. 41 (13) , 1701-1708
Identification of fetal aneuploidy with dual‐probe fluorescence in situ hybridization analysis in circulating trophoblasts after enrichment using a high‐sensitivity microfluidic platform
Objective To evaluate a microfluidics-based positive selection technology for isolating circulating trophoblasts (CTs) from peripheral blood of women whose pregnancies are affected by aneuploidy and to evaluate fetal karyotype using fluorescence in situ hybridization (FISH). Method Ten 18-ml samples of peripheral blood were collected consecutively from pregnant women whose fetus was affected by aneuploidy. A preservation buffer was added, and the specimens were shipped overnight to the testing laboratory at ambient temperature. The specimen was infused into the fully automated microfluidics-based LiquidScan® instrument without pre-processing. This instrument contains microfluidic chips, which are coated with antibodies (anti-huEpCAM and a proprietary antibody mixture) specific to CT surface epitopes. FISH analysis was performed on the enriched cells. Results Fetal aneuploidy evaluated included trisomy 21 (n = 3), trisomy 18 (n = 1), trisomy 13 (n = 1), monosomy X (n = 3), and triploidy (n = 1). CTs for analysis by FISH were identified in all samples. The average number of mononucleate cells per 1 ml of whole blood was 2.11 (range 0.38–4.63) overall and was 2.67 (range 1.13–4.63) using the proprietary combination of antibodies. FISH results were concordant with the aneuploidy based on other testing in all cases. Multinucleate cells were searched for and identified in the last seven samples (average number: 0.84/1 ml). Conclusions Our study demonstrates that the LiquidScan®, a high-sensitivity microfluidic platform, can enrich circulating trophoblasts (mononucleate and multinucleate). FISH can then be used to detect fetal aneuploidy.
- Top Cited Papers
- 17 September 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 59 (5) , 668-676
Performance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O‐RADS in differentiating between benign and malignant adnexal lesions in North American women
Objectives: To apply the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR), the IOTA Simple Rules risk assessment (SRR), the IOTA Assessment of Different NEoplasias in the adneXa (ADNEX) model and the Ovarian‐Adnexal Reporting and Data System (O‐RADS) in the same cohort of North American patients and to compare their performance in preoperative discrimination between benign and malignant adnexal lesions.Methods: This was a single‐center diagnostic accuracy study, performed between March 2018 and February 2021, which included 150 women with an adnexal lesion. Using the ADNEX model, lesions were classified prospectively, whereas the SR, SRR assessment and O‐RADS were applied retrospectively. Surgery with histological analysis was performed within 6 months of the ultrasound exam. Sensitivity and specificity were determined for each testing modality and the performance of the different modalities was compared.Results: Of the 150 women, 110 (73.3%) had a benign ovarian tumor and 40 (26.7%) had a malignant tumor. The mean risk of malignancy generated by the ADNEX model without CA 125 was significantly higher in malignant vs benign lesions (63.3% vs 11.8%) and the area under the receiver‐operating‐characteristics curve (AUC) of the ADNEX model for differentiating between benign and malignant adnexal masses at the time of ultrasound examination was 0.937. The mean risk of malignancy generated by SRR assessment was also significantly higher in malignant vs benign lesions (74.1% vs 15.9%) and the AUC was 0.941. To compare the ADNEX model, SRR assessment and O‐RADS, the malignancy risk threshold was set at ≥ 10%. This cut‐off differentiates O‐RADS low‐risk categories (Category ≤ 3) from intermediate‐to‐high‐risk categories (Categories 4 and 5). At this cut‐off, the sensitivity of the ADNEX model was 97.5% (95% CI, 85.3%–99.9%) and the specificity was 63.6% (95% CI, 53.9%–72.4%), and, for the SRR model, the sensitivity was 100% (95% CI, 89.1%–100%) and the specificity was 51.8% (95% CI, 42.1%–61.4%). In the 113 cases to which the SR could be applied, the sensitivity was 100% (95% CI, 81.5%–100%) and the specificity was 95.6% (95% CI, 88.5%–98.6%). If the remaining 37 cases, which were inconclusive under SR, were designated ‘malignant’, the sensitivity remained at 100% but the specificity was reduced to 79.1% (95% CI, 70.1%–86.0%). The 150 cases fell into the following O‐RADS categories: 17 (11.3%) lesions in Category 2, 34 (22.7%) in Category 3, 66 (44.0%) in Category 4 and 33 (22.0%) in Category 5. There were no histologically proven malignant lesions in Category 2 or 3. There were 14 malignant lesions in Category 4 and 26 in Category 5. The sensitivity of O‐RADS using a malignancy risk threshold of ≥ 10% was 100% (95% CI, 89.1%–100.0%) and the specificity was 46.4% (95% CI, 36.9%–56.1%).Conclusions: When IOTA terms and techniques are used, the performance of IOTA models in a North American patient population is in line with published IOTA results in other populations. The IOTA SR, SRR assessment and ADNEX model and O‐RADS have similar sensitivity in the preoperative discrimination of malignant from benign pelvic tumors; however, the IOTA models have higher specificity and the algorithm does not require the use of magnetic resonance imaging. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
- 17 September 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 59 (5) , 668-676
Top Cited PapersPerformance of IOTA Simple Rules, Simple Rules risk assessment, ADNEX model and O‐RADS in differentiating between benign and malignant adnexal lesions in North American women
Objectives: To apply the International Ovarian Tumor Analysis (IOTA) Simple Rules (SR), the IOTA Simple Rules risk assessment (SRR), the IOTA Assessment of Different NEoplasias in the adneXa (ADNEX) model and the Ovarian‐Adnexal Reporting and Data System (O‐RADS) in the same cohort of North American patients and to compare their performance in preoperative discrimination between benign and malignant adnexal lesions.Methods: This was a single‐center diagnostic accuracy study, performed between March 2018 and February 2021, which included 150 women with an adnexal lesion. Using the ADNEX model, lesions were classified prospectively, whereas the SR, SRR assessment and O‐RADS were applied retrospectively. Surgery with histological analysis was performed within 6 months of the ultrasound exam. Sensitivity and specificity were determined for each testing modality and the performance of the different modalities was compared.Results: Of the 150 women, 110 (73.3%) had a benign ovarian tumor and 40 (26.7%) had a malignant tumor. The mean risk of malignancy generated by the ADNEX model without CA 125 was significantly higher in malignant vs benign lesions (63.3% vs 11.8%) and the area under the receiver‐operating‐characteristics curve (AUC) of the ADNEX model for differentiating between benign and malignant adnexal masses at the time of ultrasound examination was 0.937. The mean risk of malignancy generated by SRR assessment was also significantly higher in malignant vs benign lesions (74.1% vs 15.9%) and the AUC was 0.941. To compare the ADNEX model, SRR assessment and O‐RADS, the malignancy risk threshold was set at ≥ 10%. This cut‐off differentiates O‐RADS low‐risk categories (Category ≤ 3) from intermediate‐to‐high‐risk categories (Categories 4 and 5). At this cut‐off, the sensitivity of the ADNEX model was 97.5% (95% CI, 85.3%–99.9%) and the specificity was 63.6% (95% CI, 53.9%–72.4%), and, for the SRR model, the sensitivity was 100% (95% CI, 89.1%–100%) and the specificity was 51.8% (95% CI, 42.1%–61.4%). In the 113 cases to which the SR could be applied, the sensitivity was 100% (95% CI, 81.5%–100%) and the specificity was 95.6% (95% CI, 88.5%–98.6%). If the remaining 37 cases, which were inconclusive under SR, were designated ‘malignant’, the sensitivity remained at 100% but the specificity was reduced to 79.1% (95% CI, 70.1%–86.0%). The 150 cases fell into the following O‐RADS categories: 17 (11.3%) lesions in Category 2, 34 (22.7%) in Category 3, 66 (44.0%) in Category 4 and 33 (22.0%) in Category 5. There were no histologically proven malignant lesions in Category 2 or 3. There were 14 malignant lesions in Category 4 and 26 in Category 5. The sensitivity of O‐RADS using a malignancy risk threshold of ≥ 10% was 100% (95% CI, 89.1%–100.0%) and the specificity was 46.4% (95% CI, 36.9%–56.1%).Conclusions: When IOTA terms and techniques are used, the performance of IOTA models in a North American patient population is in line with published IOTA results in other populations. The IOTA SR, SRR assessment and ADNEX model and O‐RADS have similar sensitivity in the preoperative discrimination of malignant from benign pelvic tumors; however, the IOTA models have higher specificity and the algorithm does not require the use of magnetic resonance imaging. © 2022 International Society of Ultrasound in Obstetrics and Gynecology.
- 11 January 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 57 (4) , 650-651
Detection of 69,XXX karyotype in circulating trophoblasts using fluorescence in‐situ hybridization after enrichment using novel high‐throughput microfluidic platform
- 11 January 2021
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 57 (4) , 650-651
Detection of 69,XXX karyotype in circulating trophoblasts using fluorescence in‐situ hybridization after enrichment using novel high‐throughput microfluidic platform
- 1 May 2018
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 218 (5) , 543
Reply
- 1 May 2018
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 218 (5) , 543
Reply
- 1 January 2018
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 218 (1) , 126.e1-126.e13
First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume
- 1 January 2018
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 218 (1) , 126.e1-126.e13
First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume
- Open Access
- 23 August 2016
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 50 (2) , 187-191
Sphenofrontal distance in euploid and aneuploid fetuses
- 23 August 2016
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 50 (2) , 187-191
Open AccessSphenofrontal distance in euploid and aneuploid fetuses
- 1 January 2015
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 212 (1) , S333
680: Evaluation of the prefrontal space ratio for the prenatal diagnosis of micrognathia
- 1 January 2015
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 212 (1) , S333
680: Evaluation of the prefrontal space ratio for the prenatal diagnosis of micrognathia
- 27 January 2013
- Published by Wiley in Prenatal Diagnosis
- Vol. 33 (3) , 262-268
Comparison of three methods of cervical measurement in the first trimester: single‐line, two‐line, and tracing
Objectives: To compare three methods of cervical length measurements using ultrasound in the first trimester: single‐line, two‐line, and tracing.Methods: Images appropriate for cervical length measurements were obtained using transvaginal ultrasound between 11 + 0 and 13 + 6 weeks’ gestation. The cervix was measured on stored images using three methods: a single straight line, two segments (two‐line method), and by tracing the distance along the cervical canal. Results were compared for intraoperator repeatability and interoperator variability. The degree of the cervical curvature was measured.Results: The mean cervical measurement using the single‐line measurement was 32.8 (SD 4.4) mm. The mean cervical length was essentially the same using the two‐line and tracing measurement: 34.4 (SD 4.7) mm and 34.5 (SD 4.7) mm, respectively. Both intra‐ and interoperator agreement was high. The degree of curvature of the cervical canal was variable, with a resultant variability in the difference between the single straight line measurement and the other two types of measurement.Conclusions: Using stored images, each of the measurement techniques is highly reproducible. Both the two‐line and the tracing methods yield larger measurements than the single‐line technique. Therefore, it appears that in select cases the straight line measurement significantly underestimates the actual cervical length. © 2013 John Wiley & Sons, Ltd.
- 27 January 2013
- Published by Wiley in Prenatal Diagnosis
- Vol. 33 (3) , 262-268
Comparison of three methods of cervical measurement in the first trimester: single‐line, two‐line, and tracing
Objectives: To compare three methods of cervical length measurements using ultrasound in the first trimester: single‐line, two‐line, and tracing.Methods: Images appropriate for cervical length measurements were obtained using transvaginal ultrasound between 11 + 0 and 13 + 6 weeks’ gestation. The cervix was measured on stored images using three methods: a single straight line, two segments (two‐line method), and by tracing the distance along the cervical canal. Results were compared for intraoperator repeatability and interoperator variability. The degree of the cervical curvature was measured.Results: The mean cervical measurement using the single‐line measurement was 32.8 (SD 4.4) mm. The mean cervical length was essentially the same using the two‐line and tracing measurement: 34.4 (SD 4.7) mm and 34.5 (SD 4.7) mm, respectively. Both intra‐ and interoperator agreement was high. The degree of curvature of the cervical canal was variable, with a resultant variability in the difference between the single straight line measurement and the other two types of measurement.Conclusions: Using stored images, each of the measurement techniques is highly reproducible. Both the two‐line and the tracing methods yield larger measurements than the single‐line technique. Therefore, it appears that in select cases the straight line measurement significantly underestimates the actual cervical length. © 2013 John Wiley & Sons, Ltd.
- 30 July 2012
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 40 (3) , 293-296
Prefrontal space ratio: comparison between trisomy 21 and euploid fetuses in the second trimester
Objective: To evaluate a novel ultrasound measurement, the prefrontal space ratio (PFSR), in second‐trimester trisomy 21 and euploid fetuses.Methods: Stored three‐dimensional volumes of fetal profiles from 26 trisomy 21 fetuses and 90 euploid fetuses at 15–25 weeks' gestation were examined. A line was drawn between the leading edge of the mandible and the maxilla (MM line) and extended in front of the forehead. The ratio of the distance between the leading edge of the skull and that of the skin (d1) to the distance between the skin and the point where the MM line was intercepted (d2) was calculated (d2/d1). The distributions of PFSR in trisomy 21 and euploid fetuses were compared, and the relationship with gestational age in each group was evaluated by Spearman's rank correlation coefficient (rs).Results: The PFSR in trisomy 21 fetuses (mean, 0.36; range, 0–0.81) was significantly lower than in euploid fetuses (mean, 1.48; range, 0.85–2.95; P < 0.001 (Mann–Whitney U‐test)). There was no significant association between PFSR and gestational age in either trisomy 21 (rs = 0.25; 95% CI, − 0.15 to 0.58) or euploid (rs = 0.06; 95% CI, − 0.15 to 0.27) fetuses.Conclusion: The PFSR appears to be a highly sensitive and specific marker of trisomy 21 in the second trimester of pregnancy. Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd.
- 30 July 2012
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 40 (3) , 293-296
Prefrontal space ratio: comparison between trisomy 21 and euploid fetuses in the second trimester
Objective: To evaluate a novel ultrasound measurement, the prefrontal space ratio (PFSR), in second‐trimester trisomy 21 and euploid fetuses.Methods: Stored three‐dimensional volumes of fetal profiles from 26 trisomy 21 fetuses and 90 euploid fetuses at 15–25 weeks' gestation were examined. A line was drawn between the leading edge of the mandible and the maxilla (MM line) and extended in front of the forehead. The ratio of the distance between the leading edge of the skull and that of the skin (d1) to the distance between the skin and the point where the MM line was intercepted (d2) was calculated (d2/d1). The distributions of PFSR in trisomy 21 and euploid fetuses were compared, and the relationship with gestational age in each group was evaluated by Spearman's rank correlation coefficient (rs).Results: The PFSR in trisomy 21 fetuses (mean, 0.36; range, 0–0.81) was significantly lower than in euploid fetuses (mean, 1.48; range, 0.85–2.95; P < 0.001 (Mann–Whitney U‐test)). There was no significant association between PFSR and gestational age in either trisomy 21 (rs = 0.25; 95% CI, − 0.15 to 0.58) or euploid (rs = 0.06; 95% CI, − 0.15 to 0.27) fetuses.Conclusion: The PFSR appears to be a highly sensitive and specific marker of trisomy 21 in the second trimester of pregnancy. Copyright © 2012 ISUOG. Published by John Wiley & Sons, Ltd.